Skip to main content

Table 2 Median and mean research and development spend including probability of success, cost of capital, and tax rebates

From: Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach

Category and type

Sample N

Expenditure in US$, millions

Precision vs non-precision

  

Mean

CI, 95%

Median

CI, 95%

p-value

All (inconsistent use of CDx))

86

4432.1

(3624.4–5239.7)

3160.4

(2645.9–3872.2)

 

All (CDx use consistent)

71

3973.5

(3318.0–4816.4)

2932.6

(2160.3–3438.7)

 

All precision

42

3530.6

(2729.2–4510.9)

2641.3

(2110.1–3545.7)

 

All non-precision

29

4614.9

(3532.8–6054.4)

3505.7

(2736.8–5875.3)

0.17

A&B precision

13

2475.0

(1730.7–3483.6)

2110.1

(829.5–2984.0)

 

A&B non-precision

9

6124.0

(3472.8–10,007.6)

2891.8

(2645.9–10,749.0)

0.03

C&D precision

29

4003.7

(2917.2–5422.0)

2932.6

(2018.9–3872.2)

 

C&D non-precision

20

3935.8

(3040.7–4898.4)

3787.6

(3438.7–5881.6)

0.94

  1. Legend: CDx: companion diagnostic; CIs – confidence intervals; N: number